3 results
Primary Objective- Compare the safety and efficacy of subcutaneous somavaratan and daily rhGH during 12 months of treatment.Secondary Objective-Evaluate and compare changes in pharmacodynamic responses (IGF-I, IGF binding protein-3 (IGFBP-3), growth…
See protocol page 9This study designed to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor (ICM) or newer approved version, the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for…
1) To determine whether advanced MRI techniques can detect active inflammatory Gd enhancing lesions. 2) To determine whether blood biomarkers are associated with the presence of enhancing brain lesions in MS. 3) To determine whether advanced MRI…